AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28386035 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 7020
Study 28386035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7020
Study 26450511 — intervention group
Group type: EXPERIMENTAL
Intervention: OFD plus PTGs
Number of subjects: 63
Study 26450511 — intervention group
Group type: COMPARATOR
Intervention: OFD
Number of subjects: 63
Study 25154896 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.4% glucose (CHO) solution
Number of subjects: 10
Study 25154896 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10
Study 22101206 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff-supported intervention group
Number of subjects: 0
Study 22101206 — intervention group
Group type: COMPARATOR
Intervention: Self-guided comparison group
Number of subjects: 0
Study 19708632 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene liner cementation in asymptomatic patients
Number of subjects: 34
Study 19708632 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene liner cementation in symptomatic patients
Number of subjects: 34
Study 17606839 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg
Number of subjects: 51
Study 17606839 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide 5 mg
Number of subjects: 51
Study 17606839 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide 2.5 mg
Number of subjects: 51
Study 17606839 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride 40 mg
Number of subjects: 51
Study 17606839 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 51
Study 17606839 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide
Number of subjects: 51
Study 15249932 — intervention group
Group type: EXPERIMENTAL
Intervention: EKN1 gene polymorphisms
Number of subjects: 148
Study 11242483 — intervention group
Group type: EXPERIMENTAL
Intervention: 74SeO3(2‐)
Number of subjects: 10
Study 11242483 — intervention group
Group type: EXPERIMENTAL
Intervention: 76SeO4(2‐)
Number of subjects: 10
Study 9738377 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed tip and snip technique
Number of subjects: 60
Study 9738377 — intervention group
Group type: COMPARATOR
Intervention: Divide and conquer technique
Number of subjects: 60
Study 9738377 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed tip and snip technique (patients 1-30)
Number of subjects: 60
Study 8052271 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma supernatant from platelet concentrates
Number of subjects: 12
Study 8052271 — intervention group
Group type: COMPARATOR
Intervention: Cells from platelet concentrates
Number of subjects: 12
Study 8052271 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma supernatant
Number of subjects: 12
Study 2929404 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus prednisone
Number of subjects: 52
Study 2929404 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 52
Study 2929404 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with preserved right ventricular function
Number of subjects: 52
Study 2929404 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with right ventricular diastolic dysfunction (right ventricular end-diastolic pressure >= 11 mm Hg)
Number of subjects: 52
Study 2929404 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with left ventricular ejection fraction less than 20%
Number of subjects: 52
Study 30854904 — intervention group
Group type: EXPERIMENTAL
Intervention: Trochanteric surface irregularities including frank spurs protruding ⩾2 mm
Number of subjects: 38
Study 30854904 — intervention group
Group type: COMPARATOR
Intervention: Control group (100 patients with hip osteoarthritis or intracapsular neck of femur fracture)
Number of subjects: 38
Study 31142359 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Hz TEAS
Number of subjects: 156
Study 31142359 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 Hz TEAS
Number of subjects: 156
Study 31142359 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed TEAS
Number of subjects: 156
Study 31142359 — intervention group
Group type: COMPARATOR
Intervention: Placebo TEAS
Number of subjects: 156
Study 27776752 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia for neonatal hypoxic-ischemic encephalopathy
Number of subjects: 0
Study 27776752 — intervention group
Group type: COMPARATOR
Intervention: No hypothermia (control group)
Number of subjects: 0
Study 26420002 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch Massage (TM)
Number of subjects: 20
Study 26420002 — intervention group
Group type: COMPARATOR
Intervention: Rest (Control)
Number of subjects: 20
Study 23524524 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg‐INFα‐2a
Number of subjects: 78
Study 23524524 — intervention group
Group type: COMPARATOR
Intervention: Peg‐INFα‐2b
Number of subjects: 78
Study 21412168 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (40 mg/m intravenous) weekly on day 2 + phenoxodiol (3 mg/kg) weekly on days 1 and 2
Number of subjects: 32
Study 21412168 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (80 mg/m IV) weekly on day 2 + phenoxodiol (3 mg/kg) weekly on days 1 and 2
Number of subjects: 32
Study 19638927 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure vessel sealing system (VS group)
Number of subjects: 165
Study 19638927 — intervention group
Group type: COMPARATOR
Intervention: Conventional clamp crushing method (CC group)
Number of subjects: 165
Study 17536130 — intervention group
Group type: EXPERIMENTAL
Intervention: BEEF (n = 14)
Number of subjects: 54
Study 17536130 — intervention group
Group type: EXPERIMENTAL
Intervention: CHICKEN (n = 15)
Number of subjects: 54
Study 17536130 — intervention group
Group type: EXPERIMENTAL
Intervention: CARB (n = 14)
Number of subjects: 54
Study 17536130 — intervention group
Group type: COMPARATOR
Intervention: CON (n = 11)
Number of subjects: 54
Study 17536130 — intervention group
Group type: EXPERIMENTAL
Intervention: All ER groups combined
Number of subjects: 54
Study 16264054 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway clearance techniques (chest wall percussion, vibration, huffing) during sputum induction
Number of subjects: 59
Study 16264054 — intervention group
Group type: COMPARATOR
Intervention: Standard sputum induction procedure (without airway clearance techniques)
Number of subjects: 59
Study 11916756 — intervention group
Group type: COMPARATOR
Intervention: 7 mg threonine x kg(‐1) x d(‐1)
Number of subjects: 15
Study 11916756 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg threonine x kg(‐1) x d(‐1)
Number of subjects: 15
Study 11916756 — intervention group
Group type: EXPERIMENTAL
Intervention: 46 mg threonine x kg(‐1) x d(‐1)
Number of subjects: 15
Study 9802665 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Passive Motion (CPM) machine
Number of subjects: 80
Study 9802665 — intervention group
Group type: COMPARATOR
Intervention: Professional physical therapy
Number of subjects: 80
Study 7702053 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with IDWG > 3 kg (n = 138)
Number of subjects: 860
Study 7702053 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with IDWG > 4.5% of dry weight (n = 151)
Number of subjects: 860
Study 7702053 — intervention group
Group type: COMPARATOR
Intervention: Patients with IDWG < 2 kg (n = 378)
Number of subjects: 860
Study 7702053 — intervention group
Group type: COMPARATOR
Intervention: Patients with IDWG < 3% of dry weight (n = 355)
Number of subjects: 860
Study 2533210 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole
Number of subjects: 231
Study 2533210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 33753 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkaline artificial tear preparation
Number of subjects: 20
Study 33753 — intervention group
Group type: COMPARATOR
Intervention: Current artificial tear preparations available in North America
Number of subjects: 20
Study 30445507 — intervention group
Group type: EXPERIMENTAL
Intervention: Learn to Quit (LTQ) app combined with nicotine replacement therapy and technical coaching
Number of subjects: 0
Study 30445507 — intervention group
Group type: COMPARATOR
Intervention: NCI QuitGuide (QG) app combined with nicotine replacement therapy and technical coaching
Number of subjects: 0
Study 30445507 — intervention group
Group type: EXPERIMENTAL
Intervention: Learn to Quit (LTQ) app
Number of subjects: 0
Study 27121176 — intervention group
Group type: EXPERIMENTAL
Intervention: Alex laser at 3 ms pulse duration
Number of subjects: 16
Study 27121176 — intervention group
Group type: EXPERIMENTAL
Intervention: Alex laser at 5 ms pulse duration
Number of subjects: 16
Study 27121176 — intervention group
Group type: EXPERIMENTAL
Intervention: Alex laser at 10 ms pulse duration
Number of subjects: 16
Study 27121176 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 16
Study 26018925 — intervention group
Group type: EXPERIMENTAL
Intervention: Hesperetin-7-O-rutinoside
Number of subjects: 0
Study 26018925 — intervention group
Group type: EXPERIMENTAL
Intervention: Hesperetin-7-O-glucoside
Number of subjects: 0
Study 23455591 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 79
Study 23455591 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 79
Study 23455591 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 79
Study 23455591 — intervention group
Group type: COMPARATOR
Intervention: Control (Healthy Individuals)
Number of subjects: 79
Study 21392641 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma biomarkers of inflammation (CRP, IL-6, WBC, ICAM-1)
Number of subjects: 268
Study 21392641 — intervention group
Group type: EXPERIMENTAL
Intervention: CFR measurement
Number of subjects: 268
Study 21392641 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 268
Study 18421257 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 0
Study 17012959 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-technology structured intervention including telephone and home visits, a teaching tool, digital scales, and a log/notebook filled out by the patients.
Number of subjects: 0
Study 15117037 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent placement (Crown Stent)
Number of subjects: 42
Study 15117037 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 42
Study 10096452 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorphenylamine (CP), administered daily for 7 days
Number of subjects: 0
Study 10096452 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen (FB), administered daily for 7 days
Number of subjects: 0
Study 7755942 — intervention group
Group type: EXPERIMENTAL
Intervention: 375 mg naproxen twice a day
Number of subjects: 100
Study 7755942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 2129651 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg aminophylline i.v.
Number of subjects: 12
Study 2129651 — intervention group
Group type: COMPARATOR
Intervention: 200 mg doxofylline i.v.
Number of subjects: 12
Study 2129651 — intervention group
Group type: COMPARATOR
Intervention: 400 mg doxofylline i.v.
Number of subjects: 12
Study 536100 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotapes of a same-sex adult model eating at a reduced speed
Number of subjects: 18
Study 536100 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotapes of themselves eating at a reduced speed
Number of subjects: 18
Study 536100 — intervention group
Group type: COMPARATOR
Intervention: Control condition (baseline eating behavior videotapes only)
Number of subjects: 18
Study 31226996 — intervention group
Group type: EXPERIMENTAL
Intervention: SNAPPS
Number of subjects: 18
Study 31226996 — intervention group
Group type: COMPARATOR
Intervention: Traditional case presentation
Number of subjects: 18
Study 28126304 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil/mitomycin-C/radiation therapy (Arm A)
Number of subjects: 282
Study 28126304 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil/cisplatin/radiation therapy (Arm B)
Number of subjects: 282
Study 25116574 — intervention group
Group type: EXPERIMENTAL
Intervention: Group E (bimonthly health worker‐initiated visits, counseling, and rewards for adherence)
Number of subjects: 460
Study 25116574 — intervention group
Group type: EXPERIMENTAL
Intervention: Group E
Number of subjects: 460
Study 25116574 — intervention group
Group type: COMPARATOR
Intervention: Group A (standard care services)
Number of subjects: 460
Study 22413065 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet (HP)
Number of subjects: 77
Study 22413065 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein diet (LP)
Number of subjects: 77
Study 22413065 — intervention group
Group type: COMPARATOR
Intervention: Low calorie diet (LCD)
Number of subjects: 77
Study 20649490 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa
Number of subjects: 32
Study 20649490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 17386123 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine and weekly paclitaxel
Number of subjects: 54
Study 16033307 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) + sulfadoxine‐pyrimethamine (SP)
Number of subjects: 2160
Study 16033307 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ) + sulfadoxine‐pyrimethamine (SP)
Number of subjects: 2160
Study 16033307 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ) + artesunate (AS)
Number of subjects: 2160
Study 16033307 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall risk of repeat therapy due to any recurrent infection
Number of subjects: 2160
Study 11981007 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate 2 mg IV monthly for 12 to 24 months
Number of subjects: 198
Study 11981007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 11981007 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate 2 mg IV monthly
Number of subjects: 198
Study 10207763 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in dietary caffeine intake
Number of subjects: 41
Study 10207763 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in fluid intake
Number of subjects: 41
Study 7530984 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour-infiltrating lymphocyte (TIL) infusion
Number of subjects: 9
Study 2221611 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime/clindamycin (CAZ/C)
Number of subjects: 94
Study 2221611 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin/clindamycin (T/C)
Number of subjects: 94
Study 7413691 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana cigarette (1.4% delta 9‐THC)
Number of subjects: 0
Study 7413691 — intervention group
Group type: COMPARATOR
Intervention: Placebo cigarette
Number of subjects: 0
Study 30880289 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen
Number of subjects: 111
Study 30880289 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 111
Study 27749225 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of NSAIDs
Number of subjects: 0
Study 27749225 — intervention group
Group type: COMPARATOR
Intervention: NSAID resumption upon symptom recurrence
Number of subjects: 0
Study 26482662 — intervention group
Group type: COMPARATOR
Intervention: BoNT‐A (Cycle 1, n = 23)
Number of subjects: 41
Study 26482662 — intervention group
Group type: COMPARATOR
Intervention: BoNT‐A (Cycle 2, n = 20)
Number of subjects: 41
Study 24083884 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-management (PSM)
Number of subjects: 310
Study 24083884 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 310
Study 21237636 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led telephone follow-up
Number of subjects: 320
Study 21237636 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational group programme (EGP)
Number of subjects: 320
Study 19010349 — intervention group
Group type: EXPERIMENTAL
Intervention: FV Education (FVE)
Number of subjects: 490
Study 19010349 — intervention group
Group type: COMPARATOR
Intervention: Prostate Education (PE)
Number of subjects: 490
Study 18257344 — intervention group
Group type: EXPERIMENTAL
Intervention: Slowly-releasing medication (intramuscular injection, made from Chinese herbs, administered at specific acupuncture points)
Number of subjects: 238
Study 18257344 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (Rythmol, oral administration, 150 mg thrice daily)
Number of subjects: 238
Study 17023280 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ropivacaine/fentanyl, 3 microg/mL
Number of subjects: 60
Study 17023280 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine/fentanyl, 3 microg/mL
Number of subjects: 60
Study 17023280 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study 14514745 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolized anemia management with subcutaneous rHuEpo and intravenous iron
Number of subjects: 215
Study 14514745 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 215
Study 14514745 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolized anemia management
Number of subjects: 215
Study 10810685 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled continuous infusion of lidocaine (2% solution, 2 cc/h continuous dose, 1 cc at 15-minute intervals for 72 hours)
Number of subjects: 24
Study 10810685 — intervention group
Group type: COMPARATOR
Intervention: Control group (24 patients undergoing acromioplasty without lidocaine analgesia)
Number of subjects: 24
Study 9121819 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative Pain Measure for Parents
Number of subjects: 110
Study 1666917 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral CBD (10 mg/kg/day = about 700 mg/day) for 6 weeks
Number of subjects: 14
Study 1666917 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD discontinued after 6 weeks
Number of subjects: 14
Study 1666917 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 14
Study 7105820 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg chlormezanone at night
Number of subjects: 44
Study 7105820 — intervention group
Group type: COMPARATOR
Intervention: 5 mg diazepam 3-times daily for 4 weeks
Number of subjects: 44
Study 31775877 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Diagnostic Tests (RDTs) for Cryptosporidium spp.
Number of subjects: 295
Study 31775877 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Diagnostic Tests (RDTs) for Giardia duodenalis
Number of subjects: 295
Study 31775877 — intervention group
Group type: COMPARATOR
Intervention: Multiplex PCR (reference test)
Number of subjects: 295
Study 27584142 — intervention group
Group type: COMPARATOR
Intervention: Individualized exercises (G1)
Number of subjects: 24
Study 27584142 — intervention group
Group type: COMPARATOR
Intervention: Group exercises (G2)
Number of subjects: 24
Study 27584142 — intervention group
Group type: EXPERIMENTAL
Intervention: No treatment (monitoring, G3)
Number of subjects: 24
Study 27584142 — intervention group
Group type: EXPERIMENTAL
Intervention: Raven colored matrices
Number of subjects: 24
Study 26013912 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa flavanol (CF) intake (450 mg CF) bi-daily for 14 days
Number of subjects: 42
Study 26013912 — intervention group
Group type: COMPARATOR
Intervention: Nutrient-matched, CF-free control drink bi-daily for 14 days
Number of subjects: 42
Study 24092242 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture treatment
Number of subjects: 60
Study 24092242 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine treatment
Number of subjects: 60
Study 24092242 — intervention group
Group type: COMPARATOR
Intervention: Between-group comparison for MMPI subscales paranoia and social introversion
Number of subjects: 60
Study 21540476 — intervention group
Group type: EXPERIMENTAL
Intervention: PEX eyes
Number of subjects: 42
Study 21540476 — intervention group
Group type: COMPARATOR
Intervention: Fellow eyes
Number of subjects: 42
Study 21540476 — intervention group
Group type: COMPARATOR
Intervention: Normal control eyes
Number of subjects: 42
Study 19184761 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal bar for breakfast
Number of subjects: 32
Study 19184761 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal bar as a mid-morning snack
Number of subjects: 32
Study 19184761 — intervention group
Group type: COMPARATOR
Intervention: No breakfast
Number of subjects: 32
Study 19184761 — intervention group
Group type: COMPARATOR
Intervention: No snack
Number of subjects: 32
Study 17224808 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus patient choice of acupuncture, chiropractic, or massage therapy (choice)
Number of subjects: 444
Study 17224808 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 444
Study 15363174 — intervention group
Group type: EXPERIMENTAL
Intervention: Apligraf
Number of subjects: 48
Study 15363174 — intervention group
Group type: COMPARATOR
Intervention: Split-skin graft (SSG)
Number of subjects: 48
Study 15363174 — intervention group
Group type: COMPARATOR
Intervention: Dressing
Number of subjects: 48
Study 11845944 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.1%
Number of subjects: 40
Study 11845944 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin microsphere gel 0.1%
Number of subjects: 40
Study 9726554 — intervention group
Group type: EXPERIMENTAL
Intervention: Static two-point discrimination
Number of subjects: 12
Study 9726554 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving two-point discrimination
Number of subjects: 12
Study 9726554 — intervention group
Group type: EXPERIMENTAL
Intervention: Semmes-Weinstein monofilament testing
Number of subjects: 12
Study 9726554 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinel's test
Number of subjects: 12
Study 9726554 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual motor testing of abductor pollicis brevis
Number of subjects: 12
Study 9726554 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration test
Number of subjects: 12
Study 9726554 — intervention group
Group type: EXPERIMENTAL
Intervention: Phalen's test
Number of subjects: 12
Study 9726554 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall reliability of seven tests
Number of subjects: 12